Global Protease Inhibitors Market Growth 2025-2031

Publication ID:

LPI01252202

Publication Date:

January 28, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Protease Inhibitors market size is predicted to grow from US$ 4202 million in 2025 to US$ 5572 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.
Protease inhibitors (PIs) are medications that treat viral infections. They work by preventing a virus from making more copies of itself. They"re most commonly used as an antiretroviral to manage HIV/AIDS. They can also be used to treat hepatitis C and COVID-19.
United States market for Protease Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Protease Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Protease Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Protease Inhibitors players cover CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淧rotease Inhibitors Industry Forecast鈥� looks at past sales and reviews total world Protease Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Protease Inhibitors sales for 2025 through 2031. With Protease Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Protease Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Protease Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Protease Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Protease Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Protease Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Protease Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Protease Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Reagent Grade
Pharmaceutical
Others
Segmentation by Application:
Biotechnology
Medicine
Microbiology
Agriculture
Pharmaceuticals
Food Additives
Cosmetics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSL Ltd. (Australia)
Grifols S.A (Spain)
Baxalta Incorporated (U.S.)
Octapharma AG (Switzerland)
Kedrion S.p.A (Italy)
China Biologic Products, Inc. (China)
Biotest AG (Germany)
LFB S.A (France)
Bio Product Laboratory Ltd. (U.K.)
Sanquin (Netherlands)
Key Questions Addressed in this Report
What is the 10-year outlook for the global Protease Inhibitors market?
What factors are driving Protease Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Protease Inhibitors market opportunities vary by end market size?
How does Protease Inhibitors break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Protease Inhibitors Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Protease Inhibitors by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Protease Inhibitors by Country/Region, 2020, 2024 & 2031
2.2 Protease Inhibitors Segment by Type
2.2.1 Reagent Grade
2.2.2 Pharmaceutical
2.2.3 Others
2.3 Protease Inhibitors Sales by Type
2.3.1 Global Protease Inhibitors Sales Market Share by Type (2020-2025)
2.3.2 Global Protease Inhibitors Revenue and Market Share by Type (2020-2025)
2.3.3 Global Protease Inhibitors Sale Price by Type (2020-2025)
2.4 Protease Inhibitors Segment by Application
2.4.1 Biotechnology
2.4.2 Medicine
2.4.3 Microbiology
2.4.4 Agriculture
2.4.5 Pharmaceuticals
2.4.6 Food Additives
2.4.7 Cosmetics
2.5 Protease Inhibitors Sales by Application
2.5.1 Global Protease Inhibitors Sale Market Share by Application (2020-2025)
2.5.2 Global Protease Inhibitors Revenue and Market Share by Application (2020-2025)
2.5.3 Global Protease Inhibitors Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Protease Inhibitors Breakdown Data by Company
3.1.1 Global Protease Inhibitors Annual Sales by Company (2020-2025)
3.1.2 Global Protease Inhibitors Sales Market Share by Company (2020-2025)
3.2 Global Protease Inhibitors Annual Revenue by Company (2020-2025)
3.2.1 Global Protease Inhibitors Revenue by Company (2020-2025)
3.2.2 Global Protease Inhibitors Revenue Market Share by Company (2020-2025)
3.3 Global Protease Inhibitors Sale Price by Company
3.4 Key Manufacturers Protease Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Protease Inhibitors Product Location Distribution
3.4.2 Players Protease Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Protease Inhibitors by Geographic Region
4.1 World Historic Protease Inhibitors Market Size by Geographic Region (2020-2025)
4.1.1 Global Protease Inhibitors Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Protease Inhibitors Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Protease Inhibitors Market Size by Country/Region (2020-2025)
4.2.1 Global Protease Inhibitors Annual Sales by Country/Region (2020-2025)
4.2.2 Global Protease Inhibitors Annual Revenue by Country/Region (2020-2025)
4.3 Americas Protease Inhibitors Sales Growth
4.4 APAC Protease Inhibitors Sales Growth
4.5 Europe Protease Inhibitors Sales Growth
4.6 Middle East & Africa Protease Inhibitors Sales Growth
5 Americas
5.1 Americas Protease Inhibitors Sales by Country
5.1.1 Americas Protease Inhibitors Sales by Country (2020-2025)
5.1.2 Americas Protease Inhibitors Revenue by Country (2020-2025)
5.2 Americas Protease Inhibitors Sales by Type (2020-2025)
5.3 Americas Protease Inhibitors Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Protease Inhibitors Sales by Region
6.1.1 APAC Protease Inhibitors Sales by Region (2020-2025)
6.1.2 APAC Protease Inhibitors Revenue by Region (2020-2025)
6.2 APAC Protease Inhibitors Sales by Type (2020-2025)
6.3 APAC Protease Inhibitors Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Protease Inhibitors by Country
7.1.1 Europe Protease Inhibitors Sales by Country (2020-2025)
7.1.2 Europe Protease Inhibitors Revenue by Country (2020-2025)
7.2 Europe Protease Inhibitors Sales by Type (2020-2025)
7.3 Europe Protease Inhibitors Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Protease Inhibitors by Country
8.1.1 Middle East & Africa Protease Inhibitors Sales by Country (2020-2025)
8.1.2 Middle East & Africa Protease Inhibitors Revenue by Country (2020-2025)
8.2 Middle East & Africa Protease Inhibitors Sales by Type (2020-2025)
8.3 Middle East & Africa Protease Inhibitors Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Protease Inhibitors
10.3 Manufacturing Process Analysis of Protease Inhibitors
10.4 Industry Chain Structure of Protease Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Protease Inhibitors Distributors
11.3 Protease Inhibitors Customer
12 World Forecast Review for Protease Inhibitors by Geographic Region
12.1 Global Protease Inhibitors Market Size Forecast by Region
12.1.1 Global Protease Inhibitors Forecast by Region (2026-2031)
12.1.2 Global Protease Inhibitors Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Protease Inhibitors Forecast by Type (2026-2031)
12.7 Global Protease Inhibitors Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 CSL Ltd. (Australia)
13.1.1 CSL Ltd. (Australia) Company Information
13.1.2 CSL Ltd. (Australia) Protease Inhibitors Product Portfolios and Specifications
13.1.3 CSL Ltd. (Australia) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 CSL Ltd. (Australia) Main Business Overview
13.1.5 CSL Ltd. (Australia) Latest Developments
13.2 Grifols S.A (Spain)
13.2.1 Grifols S.A (Spain) Company Information
13.2.2 Grifols S.A (Spain) Protease Inhibitors Product Portfolios and Specifications
13.2.3 Grifols S.A (Spain) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Grifols S.A (Spain) Main Business Overview
13.2.5 Grifols S.A (Spain) Latest Developments
13.3 Baxalta Incorporated (U.S.)
13.3.1 Baxalta Incorporated (U.S.) Company Information
13.3.2 Baxalta Incorporated (U.S.) Protease Inhibitors Product Portfolios and Specifications
13.3.3 Baxalta Incorporated (U.S.) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Baxalta Incorporated (U.S.) Main Business Overview
13.3.5 Baxalta Incorporated (U.S.) Latest Developments
13.4 Octapharma AG (Switzerland)
13.4.1 Octapharma AG (Switzerland) Company Information
13.4.2 Octapharma AG (Switzerland) Protease Inhibitors Product Portfolios and Specifications
13.4.3 Octapharma AG (Switzerland) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Octapharma AG (Switzerland) Main Business Overview
13.4.5 Octapharma AG (Switzerland) Latest Developments
13.5 Kedrion S.p.A (Italy)
13.5.1 Kedrion S.p.A (Italy) Company Information
13.5.2 Kedrion S.p.A (Italy) Protease Inhibitors Product Portfolios and Specifications
13.5.3 Kedrion S.p.A (Italy) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Kedrion S.p.A (Italy) Main Business Overview
13.5.5 Kedrion S.p.A (Italy) Latest Developments
13.6 China Biologic Products, Inc. (China)
13.6.1 China Biologic Products, Inc. (China) Company Information
13.6.2 China Biologic Products, Inc. (China) Protease Inhibitors Product Portfolios and Specifications
13.6.3 China Biologic Products, Inc. (China) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 China Biologic Products, Inc. (China) Main Business Overview
13.6.5 China Biologic Products, Inc. (China) Latest Developments
13.7 Biotest AG (Germany)
13.7.1 Biotest AG (Germany) Company Information
13.7.2 Biotest AG (Germany) Protease Inhibitors Product Portfolios and Specifications
13.7.3 Biotest AG (Germany) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Biotest AG (Germany) Main Business Overview
13.7.5 Biotest AG (Germany) Latest Developments
13.8 LFB S.A (France)
13.8.1 LFB S.A (France) Company Information
13.8.2 LFB S.A (France) Protease Inhibitors Product Portfolios and Specifications
13.8.3 LFB S.A (France) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 LFB S.A (France) Main Business Overview
13.8.5 LFB S.A (France) Latest Developments
13.9 Bio Product Laboratory Ltd. (U.K.)
13.9.1 Bio Product Laboratory Ltd. (U.K.) Company Information
13.9.2 Bio Product Laboratory Ltd. (U.K.) Protease Inhibitors Product Portfolios and Specifications
13.9.3 Bio Product Laboratory Ltd. (U.K.) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Bio Product Laboratory Ltd. (U.K.) Main Business Overview
13.9.5 Bio Product Laboratory Ltd. (U.K.) Latest Developments
13.10 Sanquin (Netherlands)
13.10.1 Sanquin (Netherlands) Company Information
13.10.2 Sanquin (Netherlands) Protease Inhibitors Product Portfolios and Specifications
13.10.3 Sanquin (Netherlands) Protease Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Sanquin (Netherlands) Main Business Overview
13.10.5 Sanquin (Netherlands) Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂